RPS6KA1抗体—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: 231 cells, Primary antibody: P08724(RPS6KA1 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08724(RPS6KA1 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

The RPS6KA1 antibody targets the ribosomal protein S6 kinase A1 (RPS6KA1), also known as p90 ribosomal S6 kinase 1 (RSK1), a serine/threonine kinase involved in the mitogen-activated protein kinase (MAPK) signaling pathway. RPS6KA1 plays a critical role in regulating cell proliferation, survival, and differentiation by phosphorylating downstream substrates, including transcription factors (e.g., CREB) and components of the translational machinery. Its activation is tightly linked to extracellular stimuli, such as growth factors, hormones, and cellular stress, which trigger sequential phosphorylation via ERK1/2.

RPS6KA1 antibodies are essential tools for studying its expression, localization, and activation status in various biological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate RPS6KA1's role in cancer, neurological disorders, and metabolic diseases. Specific antibodies can distinguish between inactive and phosphorylated (active) forms, often targeting residues like Ser380 or Thr573. Researchers also utilize these antibodies to explore cross-talk with other signaling pathways or assess therapeutic responses in preclinical models. Due to its involvement in oncogenic signaling, RPS6KA1 is a potential biomarker and therapeutic target, underscoring the antibody's relevance in both basic and translational research.